EP3169336A4 - Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis - Google Patents

Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis Download PDF

Info

Publication number: EP3169336A4
Authority: EP; European Patent Office
Prior art keywords: diagnosis; compositions; treating; methods; expressing cells
Prior art date: 2014-07-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP15822654.8A

Other languages

German (de)

French (fr)

Other versions

EP3169336A1 (en

Inventor

Larry Schlesinger

Eric BACHELDER

Fred COPE

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cardinal Health 414 LLC

Ohio State Innovation Foundation

Original Assignee

Cardinal Health 414 LLC

Ohio State Innovation Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-17

Filing date

2015-07-17

Publication date

2018-04-04

2015-07-17 Application filed by Cardinal Health 414 LLC, Ohio State Innovation Foundation filed Critical Cardinal Health 414 LLC

2017-05-24 Publication of EP3169336A1 publication Critical patent/EP3169336A1/en

2018-04-04 Publication of EP3169336A4 publication Critical patent/EP3169336A4/en

Status Pending legal-status Critical Current

Links

210000004027 cell Anatomy 0.000 title 1
238000003745 diagnosis Methods 0.000 title 1
210000002540 macrophage Anatomy 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
230000008685 targeting Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

EP15822654.8A 2014-07-17 2015-07-17 Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis Pending EP3169336A4 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201462025991P	2014-07-17	2014-07-17
US201462027193P	2014-07-21	2014-07-21
US201462027220P	2014-07-21	2014-07-21
US201462027733P	2014-07-22	2014-07-22
PCT/US2015/041019 WO2016011419A1 (en)	2014-07-17	2015-07-17	Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis

Publications (2)

Publication Number	Publication Date
EP3169336A1 EP3169336A1 (en)	2017-05-24
EP3169336A4 true EP3169336A4 (en)	2018-04-04

Family

ID=55079110

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP15822654.8A Pending EP3169336A4 (en)	2014-07-17	2015-07-17	Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis

Country Status (3)

Country	Link
EP (1)	EP3169336A4 (en)
CA (1)	CA2955441C (en)
WO (1)	WO2016011419A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100196272A1 (en)	2009-01-30	2010-08-05	Neoprobe Corporation	Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
JP6722663B2 (en) *	2014-07-17	2020-07-15	オハイオステートイノベーションファウンデーション	Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells, and methods of treating and diagnosing them
US10806803B2 (en)	2014-07-17	2020-10-20	Ohio State Innovation Foundation	Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
CA3039519A1 (en) *	2016-10-04	2018-04-12	Cardinal Health 414, Llc	Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
US11369680B2 (en)	2016-10-07	2022-06-28	Navidea Biopharmaceuticals, Inc.	Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
JP2020528059A (en) *	2017-07-21	2020-09-17	ナビディア・バイオファーマシューティカルズ，インコーポレーテッド	Use of 99mTc tilmanocept and related molecular structures to identify and diagnose malignancies and to monitor therapeutic antitumor interventions
EP3844500A4 (en) *	2018-08-27	2022-05-11	NantBio, Inc.	Rp182 compositions and methods
JP2022527176A (en) *	2019-03-27	2022-05-31	ナビディア、バイオファーマスーティカルズ、インコーポレイテッド	Compositions and Methods for Modifying Macrophage Phenotypes
MX2022003699A (en) *	2019-09-30	2022-07-13	Navidea Biopharmaceuticals Inc	Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands.
US11859023B2 (en)	2020-07-08	2024-01-02	Navidea Biopharmaceuticals, Inc.	Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
WO2023150695A1 (en)	2022-02-04	2023-08-10	Navidea Biopharmaceuticals, Inc.	Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1069820A (en) *	1965-12-21	1967-05-24	Akad Wissenschaften Ddr	Tuberculostatic compounds
US6409990B1 (en) *	1999-05-14	2002-06-25	The Regents Of The University Of California	Macromolecular carrier for drug and diagnostic agent delivery
WO2012169973A1 (en) *	2011-06-09	2012-12-13	Agency For Science, Technology And Research	A core-shell nanoparticle
WO2016011415A2 (en) *	2014-07-17	2016-01-21	Ohio State Innovation Foundation	Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same

2015
- 2015-07-17 CA CA2955441A patent/CA2955441C/en active Active
- 2015-07-17 WO PCT/US2015/041019 patent/WO2016011419A1/en active Application Filing
- 2015-07-17 EP EP15822654.8A patent/EP3169336A4/en active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1069820A (en) *	1965-12-21	1967-05-24	Akad Wissenschaften Ddr	Tuberculostatic compounds
US6409990B1 (en) *	1999-05-14	2002-06-25	The Regents Of The University Of California	Macromolecular carrier for drug and diagnostic agent delivery
WO2012169973A1 (en) *	2011-06-09	2012-12-13	Agency For Science, Technology And Research	A core-shell nanoparticle
WO2016011415A2 (en) *	2014-07-17	2016-01-21	Ohio State Innovation Foundation	Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COESSENS V ET AL: "Synthesis of polyglutamine and dextran conjugates of streptomycin with an acid-sensitive drug-carrier linkage", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 38, no. 2, 1 February 1996 (1996-02-01), pages 141 - 150, XP004037399, ISSN: 0168-3659, DOI: 10.1016/0168-3659(95)00111-5 *
DOU HONGJING ET AL: "Facile preparation and drug delivery behavior of novel dextran-based nanogels conjugated with doxorubicin via a pH-labile bond", JOURNAL OF CONTROLLED RELEASE, vol. 172, no. 1, 2013, XP028773131, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2013.08.139 *
See also references of WO2016011419A1 *

Also Published As

Publication number	Publication date
WO2016011419A1 (en)	2016-01-21
EP3169336A1 (en)	2017-05-24
CA2955441C (en)	2023-03-14
CA2955441A1 (en)	2016-01-21

Legal Events

Date	Code	Title	Description
2017-02-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2017-04-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-04-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-05-24	17P	Request for examination filed	Effective date: 20170209
2017-05-24	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-05-24	AX	Request for extension of the european patent	Extension state: BA ME
2017-10-25	DAV	Request for validation of the european patent (deleted)
2017-10-25	DAX	Request for extension of the european patent (deleted)
2017-11-15	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: CARDINAL HEALTH 414, LLC Owner name: OHIO STATE INNOVATION FOUNDATION Owner name: COPE, FRED Owner name: SCHLESINGER, LARRY Owner name: BACHELDER, ERIC
2018-04-04	A4	Supplementary search report drawn up and despatched	Effective date: 20180301
2018-04-04	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/721 20060101ALN20180223BHEP Ipc: A61P 35/00 20060101ALI20180223BHEP Ipc: A61K 47/54 20170101ALI20180223BHEP Ipc: A61P 31/06 20060101ALI20180223BHEP Ipc: A61K 49/00 20060101ALI20180223BHEP Ipc: A61K 47/61 20170101AFI20180223BHEP
2020-01-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2020-02-26	17Q	First examination report despatched	Effective date: 20200122
2020-11-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS

Publication	Publication Date	Title
EP3169336A4 (en)	2018-04-04	Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
EP3377042A4 (en)	2019-05-29	Materials and methods for treatment of titin-based myopathies and other titinopaties
EP3313404A4 (en)	2019-08-07	Therapeutic compositions, combinations, and methods of use
EP3328399A4 (en)	2019-01-02	Modified cells and methods of therapy
EP3368559A4 (en)	2020-01-15	Compositions and methods for treatment of cancer
EP3288958A4 (en)	2018-09-26	Compositions of obeticholic acid and methods of use
EP3230460A4 (en)	2018-06-20	Methods and compositions for selectively eliminating cells of interest
EP3218390A4 (en)	2018-11-21	Targeted xten conjugate compositions and methods of making same
EP3218492A4 (en)	2018-10-10	Disruption and field enabled delivery of compounds and compositions into cells
EP3094720A4 (en)	2017-08-02	Compositions and methods of preparing airway cells
EP3167046A4 (en)	2017-12-20	Manufacture and cryopreservation of fucosylated cells for therapeutic use
EP3134130A4 (en)	2018-04-04	Compositions and methods to treating hemoglobinopathies
EP3207048A4 (en)	2018-05-30	Compositions and methods of treating muscular dystrophy
EP3139935A4 (en)	2017-11-15	Therapeutic placental compositions, methods of making and methods of use
EP3341391A4 (en)	2019-03-06	Compositions and methods for treatment of pain
EP3256110A4 (en)	2018-11-21	Compositions and methods of tumor treatment utilizing nanoparticles
EP3186286A4 (en)	2018-04-25	Cellulose-containing compositions and methods of making same
EP3169792A4 (en)	2018-04-11	Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
EP3021839A4 (en)	2017-05-31	Methods and compositions for treatment of fibrosis
EP3139928A4 (en)	2017-12-13	Anordrin compositions and methods for treating diseases
EP3353204A4 (en)	2019-06-19	Methods and compositions for treatment of cancer
EP3151786A4 (en)	2018-01-10	Compositions and methods for regeneration of hard tissues
EP3105327A4 (en)	2017-10-18	Compositions and methods of using microrna inhibitors
EP3352771A4 (en)	2019-04-24	Umbilical tissue compositions and methods of use
EP3125963A4 (en)	2017-11-29	Tissue filler compositions and methods of use